---
schema_version: "secwatch.filing_event.v1"
accession: "0001559053-24-000023"
form_type: "8-K"
ticker: "PRTA"
cik: "0001559053"
company_name: "PROTHENA CORP PUBLIC LTD CO"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:54:06.694833+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Prothena Q2 net income $66.9M; BMS licenses PRX019 for $80M; year-end cash guidance raised to $468M

## Summary
- Q2 net income $66.9M (diluted EPS $1.22) vs net loss $54.6M in Q2 2023; revenue $132M vs $4M.
- BMS obtained exclusive global license for PRX019 for $80M upfront; potential milestones up to $617.5M.
- Year-end cash guidance raised to ~$468M from $405M; net cash used guidance reduced to $148-160M.
- Topline results expected: prasinezumab Phase 2b (2H 2024), birtamimab Phase 3 (4Q24-2Q25), coramitug Phase 2 (1H25).
- Cash and restricted cash $565M as of June 30, 2024; no debt; ~53.8M shares outstanding.

## SEC filing metadata
- accession: 0001559053-24-000023
- form_type: 8-K
- ticker: PRTA
- cik: 0001559053
- company_name: PROTHENA CORP PUBLIC LTD CO
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1559053/000155905324000023/0001559053-24-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1559053/000155905324000023/prta-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001559053-24-000023
- JSON: https://secwatch.observer/filing/0001559053-24-000023.json
- Plain text: https://secwatch.observer/filing/0001559053-24-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.